Are you eagerly awaiting news of FDA approval for low dose atropine for myopia management? Several pharmaceutical companies are pursuing FDA approval and are finalizing Phase III clinical studies for review. Currently low dose atropine for myopia management is prescribed as an off-label use by doctors to slow the progression of myopia, backed by numerous international studies including the ATOM 1 and 2...

Is your child near-sighted (or myopic)?  Chances are, their prescription is only going to increase as they grow!  Myopia progression is something that I discuss with worried parents daily.  Many parents have high prescriptions themselves, and would love to save their child from the difficulties involved with highly myopic prescriptions. Unfortunately trying to prevent this from happening is a difficult battle. On average,...